CN114746101A - 应激障碍的预防或改善用剂和包含其的组合物 - Google Patents
应激障碍的预防或改善用剂和包含其的组合物 Download PDFInfo
- Publication number
- CN114746101A CN114746101A CN202080083597.4A CN202080083597A CN114746101A CN 114746101 A CN114746101 A CN 114746101A CN 202080083597 A CN202080083597 A CN 202080083597A CN 114746101 A CN114746101 A CN 114746101A
- Authority
- CN
- China
- Prior art keywords
- preventing
- agent
- stress disorder
- lactic acid
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000013200 Stress disease Diseases 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims description 42
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 106
- 241000894006 Bacteria Species 0.000 claims abstract description 60
- 239000004310 lactic acid Substances 0.000 claims abstract description 53
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 53
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 37
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims abstract description 11
- 235000013325 dietary fiber Nutrition 0.000 claims description 26
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 13
- 229920002581 Glucomannan Polymers 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 13
- 229940046240 glucomannan Drugs 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 229920002670 Fructan Polymers 0.000 claims description 6
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 6
- 229920001715 Porphyran Polymers 0.000 claims description 6
- 208000019116 sleep disease Diseases 0.000 claims description 6
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 206010029333 Neurosis Diseases 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 208000015238 neurotic disease Diseases 0.000 claims description 4
- 208000019906 panic disease Diseases 0.000 claims description 4
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 claims description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 244000215068 Acacia senegal Species 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 3
- 229920002498 Beta-glucan Polymers 0.000 claims description 3
- 241001474374 Blennius Species 0.000 claims description 3
- 208000020401 Depressive disease Diseases 0.000 claims description 3
- 229920000855 Fucoidan Polymers 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 229920000084 Gum arabic Polymers 0.000 claims description 3
- 229920001202 Inulin Polymers 0.000 claims description 3
- 229920001543 Laminarin Polymers 0.000 claims description 3
- 239000005717 Laminarin Substances 0.000 claims description 3
- 229920001100 Polydextrose Polymers 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 239000000205 acacia gum Substances 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 3
- 229940029339 inulin Drugs 0.000 claims description 3
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims description 3
- 235000010449 maltitol Nutrition 0.000 claims description 3
- 239000000845 maltitol Substances 0.000 claims description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 3
- 229940035436 maltitol Drugs 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- 239000001814 pectin Substances 0.000 claims description 3
- 229920001277 pectin Polymers 0.000 claims description 3
- 229960000292 pectin Drugs 0.000 claims description 3
- 235000013856 polydextrose Nutrition 0.000 claims description 3
- 239000001259 polydextrose Substances 0.000 claims description 3
- 229940035035 polydextrose Drugs 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- 235000010451 Plantago psyllium Nutrition 0.000 claims description 2
- 244000090599 Plantago psyllium Species 0.000 claims description 2
- 210000000467 autonomic pathway Anatomy 0.000 claims description 2
- 208000020685 sleep-wake disease Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 description 20
- 239000002775 capsule Substances 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 12
- 239000000843 powder Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- -1 infusions Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 208000028173 post-traumatic stress disease Diseases 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 4
- 208000026345 acute stress disease Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010016754 Flashback Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000009223 counseling Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010049976 Impatience Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 208000035755 Psychosomatic disease Diseases 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 230000001814 effect on stress Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000021105 fermented cheese Nutrition 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000009898 traumatic memory Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/24—Cellulose or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/137—Delbrueckii
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
以提供安全性和有效性高、副作用少、能够长期连续使用的应激障碍的预防或改善用剂作为目的。本发明的一个方案是一种应激障碍的预防或改善用剂,乳酸菌德氏乳杆菌乳亚种或来源于该乳酸菌的成分作为有效成分。
Description
技术领域
本发明涉及用于预防、治疗或改善应激障碍的制剂和组合物,进一步具体而言,涉及以乳酸菌和/或来源于乳酸菌的成分作为有效成分的应激障碍的预防、治疗或改善用剂和包含其的组合物。
背景技术
应激障碍是以应激为原因而发生的身体和/或心灵的障碍。应激障碍可以分类为以下三组。
1.适应障碍
适应障碍是不能适应环境的变化而招致身心状况不佳而变为适应不良的状态,根据ICD-10(世界卫生组织的诊断指导原则),被定义为“是因为应激原因而引起的情绪方面、行动方面的症状,是社会性机能被显著阻碍的状态”。作为适应障碍的症状,可举出焦虑、愤怒、急躁、紧张等情绪方面的症状、和暴饮暴食、鲁莽驾驶等攻击性行为、儿童的情况下的“婴儿退行”等行为方面的症状。此外,作为身体的症状,也有时观察到自主神经功能紊乱(出汗、心悸、头晕、神经症性反应等)的症状。适应障碍也有时作为抑郁反应、抑郁症、神经症性反应、躁郁症、焦虑症、惊恐障碍、睡眠障碍、癫痫、精神***症、非典型精神病等而出现(被诊断)。
2.急性应激障碍
急性应激障碍基于包含闪回现象等侵入症状、消极情绪、分离症状、回避症状、觉醒症状等在“Diagnostic and Statistical Manual of Mental Disorders,FifthEdition”(DSM-5)中被推荐的基准等来诊断。患者有时直接或间接地曝露于创伤事件,反复地想起心理创伤的记忆,呈现睡眠障碍、集中困难等症状。急性应激障碍虽然引起持续3天以上的显著的痛苦,但与心理创伤后应激障碍(PTSD)不同,不会持续1个月以上。患者的症状有时也作为体内稳态的障碍(由自主神经***、内分泌***、免疫***引起的身心疾病、过度适应状态、神经性厌食症、神经性贪食症等)、精神障碍(抑郁反应、神经症性反应、躁郁症、焦虑症、惊恐障碍、睡眠障碍等)而出现。
3.心理创伤后应激障碍(PTSD)
心理创伤后应激障碍是通过起因于直接或间接体验的、感到恐怖感、无力感、或战栗的事件(例如,自己或他人负重伤或处于死亡威胁的战斗、性暴行、自然灾害、人祸)等的、不太想要接受的应激,从而变为不适应的状态。对于心理创伤后应激障碍,有时观察到创伤事件的恶梦、闪回现象、感情上的麻痹、抑郁症、其它焦虑症、药物滥用、睡眠障碍等症状,也有时作为急性应激障碍的后续而出现。诊断基于DSM-5的基准在临床上进行。
应激障碍按照各自的诊断基准,主要通过充分的问诊、心理测试来诊断。心理测试中有多种,例如,“Comprehensive Health Check for Workers”(CHCW;働く人のこころとからだの早期健康チェック(劳动者的心灵和身体的早期健康检查))是为了应激状态的早期发现而开发,也用于功能性病况的诊断(非专利文献1、非专利文献2)。
作为以往的应激障碍的治疗法,有咨询(精神分析、认知行为疗法、存在疗法等)、药物疗法(抗抑郁剂、抗焦虑剂等精神药物、抗精神病药、中药方剂等)、物理疗法(转地疗法、温泉疗法等)等。
然而,现在的药物疗法所使用的药物中有时副作用多,由此使患者痛苦。在咨询、物理疗法中,有时经济负担、时间负担过度花费,持续变得困难。因此,期望更安全且有效的、对患者负担少的治疗手段。
近年来,在健康的维持和改善中功能性乳酸菌受到关注,大量菌株被分离,研究了它们的有用性。德氏乳杆菌乳亚种KLAB-4株(Lactobacillus delbrueckii subsp.lactisKLAB-4)是从发酵乳被分离出的菌株,作为属于乳杆菌属德氏乳杆菌种乳亚种的新的乳酸菌,被保藏在独立行政法人制品评价技术基盘机构(日本国千叶县木更津市かずさ镰足2-5-8)(保藏编号NITE BP-394;将原保藏日2007年8月9日的国内保藏株向基于布达佩斯条约的国际保藏转移(2008年9月22日))。已知该乳酸菌具有优异的抗***反应功能,进一步具有抗自身免疫疾病功能、糖尿病改善功能和低血糖改善功能(专利文献1和2、非专利文献3)。
现有技术文献
专利文献
专利文献1:日本专利第5554994号公报
专利文献2:日本专利第6747724号公报
非专利文献
非专利文献1:“働く人のこころとからだの早期健康チェック(Comprehensivehealth Check for Workers,CHCW)質問紙の新規開発”,津田彰,下光辉一,小田切优子,伏島あゆみ,田中芳幸,冈村尚昌,山口英世,山本哲郎,Harald Mori,Alexander Batthyany,Amarendra N.Singh,永田胜太郎,全人的医療11(1),2-28(2012)
非专利文献2:“Comprehensive health Check for Workers(CHCW)による線維筋痛症患者の評価”,永田胜太郎,近藤麻乃,津田彰,伏岛あゆみ,Jpn J Psychosom MedVol.54No.11,1039-1046(2014)
非专利文献3:“乳酸菌の健康機能”,立垣爱郎,全人的医療17(1),8-19(2018)
发明内容
发明所要解决的课题
本发明的目的是提供安全性和有效性高、副作用少、能够长期连续使用的应激障碍的预防或改善用剂。
用于解决课题的手段
本发明人为了解决上述课题而进行了深入研究,结果发现,特定的乳酸菌显示优异的应激障碍的预防或改善作用,完成了本发明。
根据本发明,提供:
〔1〕一种应激障碍的预防或改善用剂,以作为乳酸菌的德氏乳杆菌乳亚种(Lactobacillus delbrueckii subsp.lactis)或来源于该乳酸菌的成分作为有效成分;
〔2〕根据上述〔1〕所述的应激障碍的预防或改善用剂,上述应激障碍为适应障碍、自主神经功能紊乱、抑郁反应、抑郁症、神经症性反应、躁郁症、焦虑症、惊恐障碍、睡眠障碍、癫痫、精神***症、非典型精神病中的任意1种以上;
〔3〕根据上述〔1〕或〔2〕所述的应激障碍的预防或改善用剂,上述乳酸菌包含选自德氏乳杆菌乳亚种KLAB-4株(NITE BP-394)及其突变体中的乳酸菌;
〔4〕根据上述〔1〕~〔3〕中任一项所述的应激障碍的预防或改善用剂,进一步含有水溶性食物纤维成分,或者与水溶性食物纤维成分联合使用;
〔5〕根据上述〔4〕所述的应激障碍的预防或改善用剂,上述水溶性食物纤维成分从葡甘露聚糖、果胶、瓜尔豆胶、海藻酸、聚右旋糖、β葡聚糖、果聚糖、菊糖、Levan型果聚糖、Graminan型果聚糖、***胶、麦芽糖醇、洋车前子、难消化性寡糖、难消化性糊精、琼脂糖、海藻酸钠、卡拉胶、岩藻多糖、紫菜聚糖(porphyran)、昆布多糖、海藻和琼脂中选择;
〔6〕根据上述〔5〕所述的应激障碍的预防或改善用剂,上述水溶性食物纤维成分为葡甘露聚糖;
〔7〕一种组合物,包含上述〔1〕~〔6〕中任一项所述的应激障碍的预防或改善用剂;
〔8〕一种药物组合物,包含上述〔1〕~〔6〕中任一项所述的应激障碍的预防或改善用剂;
〔9〕一种饮食品组合物,包含上述〔1〕~〔6〕中任一项所述的应激障碍的预防或改善用剂;
〔10〕一种动物用饲料或动物用药物组合物,包含上述〔1〕~〔6〕中任一项所述的应激障碍的预防或改善用剂;
〔11〕一种应激障碍的预防或改善方法,包括:向对象施与上述〔1〕~〔6〕中任一项所述的应激障碍的预防或改善用剂、或上述〔7〕~〔10〕中任一项所述的组合物。
发明的效果
本发明的应激障碍的预防或改善用剂和包含其的组合物能够有效地改善应激障碍。本发明的、应激障碍的改善用剂和包含其的组合物由于以安全性高的乳酸菌或来源于该乳酸菌的成分作为有效成分,因此即使长期施与或摄取,也没有副作用的担心,安全性高。此外,水溶性食物纤维成分例如葡甘露聚糖也还对于人类而言是具有长年的食用经验的有益成分,安全性高。因此,本发明的应激障碍的改善用剂和包含其的组合物也能够使用于预防,也能够使用于治疗。
附图说明
图1为表示将CHCW的数值在施与前后进行了比较的变化的图。“**”表示相对于前值p<0.01,“***”表示相对于前值p<0.001。
图2为表示各组的CHCW的变化率(%)的图。“**”表示相对于P组p<0.01,“***”表示相对于P组p<0.001。“※※”表示相对于L组p<0.01。
具体实施方式
本发明的应激障碍的预防或改善用剂以乳酸菌德氏乳杆菌乳亚种或来源于该乳酸菌的成分作为有效成分。因此,本发明的制剂可以仅由乳酸菌德氏乳杆菌乳亚种或来源于该乳酸菌的成分构成,也可以包含其它有效成分。
<乳酸菌>
在本发明中使用的乳酸菌德氏乳杆菌乳亚种可以从发酵乳或干酪等发酵食品等分离,或者也可以获得被分离出的菌株而使用。作为在本发明中使用的乳酸菌,期望包含选自德氏乳杆菌乳亚种KLAB-4株(Lactobacillus delbrueckii subsp.lactis KLAB-4,以下也称为“KLAB-4株”)及其突变体中的乳酸菌。
KLAB-4株为专利文献1(日本专利第5554994号公报)中详细记载的菌株。该菌株由于确认了其从16s rRNA基因的5’末端的碱基到第544号碱基的序列与乳杆菌属德氏乳杆菌种乳亚种标准株具有90%以上的同源性,因此被鉴定为乳杆菌属德氏乳杆菌种乳亚种。
关于本发明中的使用,优选的乳酸菌不仅为KLAB-4株,也可以为其突变体。这样的突变体没有特别限定,可以为由自发突变得到的菌株、通过对放射线或突变诱导物质的曝露等公知的方法而人工诱导突变而获得的菌株等。突变体只要是与KLAB-4乳酸菌相比具有同等的特性(特别是,应激障碍的预防或改善作用)的菌株,就可以在本发明中使用。
乳酸菌德氏乳杆菌乳亚种例如KLAB-4株或其突变体可以通过公知的一般的培养基和方法来培养。这些乳酸菌通过使用这些菌能够生长繁殖的培养基例如MRS培养基,在一般的培养条件下,在通常使用的发酵罐、试管、瓶、烧瓶等容器中进行通常的乳酸菌培养,从而可以进行培养。
在本发明中使用的乳酸菌可以为活菌,也可以为死菌。所谓活菌,是指活着的菌体,所谓死菌,是指通过加热、加压、利用药物等的处理而被杀菌了的菌体。
进一步,由乳酸菌获得的来源于乳酸菌的成分也只要具有同等的功能,就可以与菌体同样地在本发明中使用。所谓来源于乳酸菌的成分,是指菌体的部分或成分、或包含它们的任一者的物质,例如,是指向乳酸菌实施磨碎、破碎、提取、分级、干燥、加热、冷冻、冷却、浓缩、稀释等处理的至少一者而获得的菌体处理物等。来源于乳酸菌的成分可以为液体、糊料、粉末、颗粒等任意形态。可以使用从菌体提取了某种成分后的残渣,例如,可以使用热水提取后的残渣。
KLAB-4株乳酸菌粉末作为商品名“乳酸菌LAB4”(株式会社カネカ制)而被市售,因此可以使用该市售品。
<水溶性食物纤维成分>
在本发明的应激障碍的预防或改善用剂中,除了如上所述的乳酸菌或来源于乳酸菌的成分以外,还可以包含水溶性食物纤维成分。发现通过进一步包含这样的成分,从而本发明的制剂的效果被增强。
所谓水溶性食物纤维成分,是指水溶性食物纤维、或包含其的食品/药物或食品/药物原材料。作为水溶性食物纤维成分的具体例,可举出例如,葡甘露聚糖、果胶、瓜尔豆胶、海藻酸、聚右旋糖、β葡聚糖、果聚糖、菊糖、Levan型果聚糖、Graminan型果聚糖、***胶、麦芽糖醇、洋车前子、难消化性寡糖、难消化性糊精、琼脂糖、海藻酸钠、卡拉胶、岩藻多糖、紫菜聚糖(porphyran)、昆布多糖、以及海藻和琼脂等天然或合成的水溶性食物纤维或含有水溶性食物纤维的材料。
可以使水溶性食物纤维成分预先含有于本发明的制剂,也可以在施与或摄取时与乳酸菌或来源于乳酸菌的成分一起。或者,也可以作为含有各自的分开的调制物而施与或摄取,在该情况下,也可以将两者同时,或时间上前后施与或摄取。换言之,本发明的制剂或组合物不仅有在同一组合物中包含乳酸菌或来源于乳酸菌的成分、和水溶性食物纤维成分的情况,而且也可以作为分开的制剂或组合物而同时或前后施与或摄取。例如,可以使被封入到胶囊的形态的本发明的制剂用包含水溶性食物纤维成分的饮料服用。
在使本发明的制剂含有水溶性食物纤维成分的情况下或将本发明的制剂与水溶性食物纤维成分联合使用的情况下,其比例(重量比)没有特别限定,例如相对于乳酸菌或来源于乳酸菌的成分1份,优选为水溶性食物纤维成分0.1~2份左右。
通过水溶性食物纤维成分而乳酸菌的效果被增强的作用机理不明,本发明不受特定的作用机理束缚。例如,葡甘露聚糖由于亲水性高,可以吸收相对于葡甘露聚糖的重量为约100倍的重量的水,因此可以认为葡甘露聚糖通过在胃内吸水从而体积增加到约100倍,成为在胃粘膜覆盖了薄膜的状态。因此,作为一个可能性,可以认为通过水溶性食物纤维成分存在从而可以调节乳酸菌的吸收。
<其它成分>
本发明的应激障碍的预防或改善用剂虽然以如上所述的乳酸菌或来源于乳酸菌的成分作为唯一的必需成分,但可以含有或联合使用水溶性食物纤维成分那样的其它有效成分。包含本发明的应激障碍的预防或改善用剂的组合物除了本发明的制剂以外,还包含一种以上的其它成分。
本发明的组合物可以为药物组合物、饮食品组合物、动物用饲料组合物或动物用药物组合物等,它们的具体的形态没有特别限定。例如,在使用本发明的组合物作为药物的情况下,作为其形态或剂型,可举出胶囊剂、片剂、丸剂、散剂、颗粒剂、饮料剂、糖浆剂、注射剂、输液、滴鼻剂、滴眼剂、栓剂、贴附剂、喷雾剂等。在使用本发明的组合物作为饮食品组合物的情况下,可以与各种食品原材料或成分一起制成一般食品的形态,此外,也可以制成胶囊剂或片剂等形态的补充剂等功能性食品。
本发明的组合物所包含的任意的成分可以根据组合物的性质、形态、制造方法等来适当选择,可以为在制药、食品、化妆品等业界中公知的各种成分、添加剂。作为本发明的组合物可以包含的添加剂,可以举出药剂学上可容许的、或在制药、食品、化妆品等业界中被日常使用的、赋形剂、崩解剂、滑润剂、粘合剂、表面活性剂、流动性促进剂、着色剂、溶剂、增稠剂、分散剂、pH调节剂、保湿剂、稳定剂、保存料、香料等。
这些添加剂根据所希望的剂型等来适当选择。例如,在本发明的药物组合物或饮食品组合物等组合物为粉末剂、颗粒剂、片剂、胶囊剂等形态的情况下,作为所使用的赋形剂,有乳糖、蔗糖、葡萄糖、山梨糖醇、乳糖醇等单糖或二糖类、玉米淀粉、马铃薯淀粉那样的淀粉类、结晶纤维素,作为无机物,有轻质硅胶、合成硅酸铝、偏硅酸铝酸镁、磷酸氢钙、二氧化硅等。此外,根据需要,可以适当使用粘合剂、崩解剂、表面活性剂、滑润剂、流动性促进剂、抗氧化剂、凝集防止剂、吸收促进剂、助溶剂、稳定剂、防腐剂、防潮剂、着色剂、香料等。
作为粘合剂,可举出例如,淀粉、糊精、***胶末、明胶、羟基丙基淀粉、羧基甲基纤维素·钠盐、甲基纤维素、结晶性纤维素、乙基纤维素、聚乙烯吡咯烷酮。
作为崩解剂,有淀粉类、羧基甲基纤维素(CMC)、羟基丙基纤维素(HPC)、羧基甲基纤维素·钠盐、聚乙烯吡咯烷酮等。
作为表面活性剂,可举出大豆卵磷脂、蔗糖脂肪酸酯等,作为滑润剂,可举出滑石、蜡、蔗糖脂肪酸酯、氢化植物油、硬脂酸钙、硬脂酸镁等,作为流动性促进剂,可举出硅酸酐、干燥氢氧化铝、硅酸镁等。
在使用本发明的组合物作为动物用饲料或动物用药物组合物的情况下,也与上述同样,可以使用各种饲料原材料或药剂学上可容许的成分,制成饲料、补充剂、医药等所希望的形态或剂型。
本发明的制剂或组合物可以单独施与或使用,也可以与其它药剂联合使用。此外,在将本发明的制剂或组合物与其它药剂联合使用的情况下,可以将两者同时使用,也可以前后使用。
本发明的应激障碍的预防或改善用剂、或组合物的施与(或摄取或应用)途径例如可以从经口、经皮、经肠、直肠内途径等适当选择。对于应激障碍的预防或改善而言有效的本发明的制剂或组合物的每1天的施与(或摄取或应用)量根据其制剂形态、施与等的方法、途径、对象者的年龄和体重、疾病的重症度等而不同,例如在经口途径的情况下,对于人,一般而言,作为有效成分的乳酸菌或来源于乳酸菌的成分的量,可以将约0.1mg~约1000mg/kg体重/天,优选为约1mg~约500mg/kg体重/天,最优选为约2mg~约300mg/kg体重/天一次或分开而施与或摄取。施与或摄取的时机没有特别限定,例如,可以为与进餐同时、刚进餐后、即将进餐前、睡眠前等。
本发明的制剂或组合物由于安全性非常高,因此不仅可以向患者而且也可以向健康者给予。此外,本发明的制剂或组合物可以同样地施与(或摄取或应用)对象,具体而言为人和除人以外的动物,优选为哺乳类。作为除人以外的动物的例子,可举出牛、马、猪、绵羊等家畜、和犬、猫等伴侣动物。关于施与量,可以以与上述同样的量作为基准,根据动物的特性来调整。例如,在小动物的情况下,作为乳酸菌或来源于乳酸菌的成分量,可以以成为相当于约0.01~约1000mg/kg体重/天、更优选为约0.1~约30mg/kg体重/天的施与或摄取量的方式调整而给予。
通过本发明的制剂或组合物,应激障碍是否被改善可以通过在施与或摄取前和后、或施与或摄取中或后等不同时刻,调查与前时刻相比在后时刻症状数和/或程度是否增减来评价。
作为应激障碍的评价方法,可以通过基于上述那样的诊断基准的医生的诊察来进行,但使用CHCW是有利的。CHCW为由身体(肉体)/心理(心灵)/社会(环境)/存在(生存意义)这4个分类构成的30项目的问卷,是简便并且可耐统计学研究的问卷法(非专利文献1、非专利文献2)。通过CHCW进行一定基准下的数值化,从而可以客观地比较或评价应激障碍的有无或程度。
实施例
以下显示例子更具体地说明本发明,但本发明不受这些实施例任何限定。
1.胶囊剂的制造
作为乳酸菌德氏乳杆菌乳亚种,使用KLAB-4乳酸菌粉末(商品名“乳酸菌LAB4”(株式会社カネカ制)),作为水溶性食物纤维成分,使用葡甘露聚糖(商品名“レオレックスRS”(清水化学株式会社制)),制造出以下3种胶囊剂。
制造例1:
每1胶囊,将乳酸菌粉末100mg、葡甘露聚糖粉末50mg、结晶纤维素粉末17.5mg、硬脂酸钙粉末2mg、二氧化硅粉末0.5mg混合、搅拌而使其均匀后,填充于市售的胶囊(商品名“ブタゼラチンクリア3号”(クオリカプス株式会社制))。
制造例2:
每1胶囊,将乳酸菌粉末100mg、乳糖50mg、结晶纤维素粉末17.5mg、硬脂酸钙粉末2mg、二氧化硅粉末0.5mg混合、搅拌而使其均匀后,填充于与在制造例1中使用的物质相同的市售的胶囊。
比较例:
代替乳酸菌粉末和葡甘露聚糖粉末,而包含乳糖150mg,除此以外,制造出与制造例1相同的胶囊剂。
这些3种胶囊剂在外观、味道、气味上都没有差别,不区别。
2.对应激障碍的效果的试验
本研究在(公财)国际全人医疗研究所的伦理委员会的承认的基础上,获得充分的知情同意而实施(2017年,研究期间:2017年12月~2019年6月)。
<受检者>
将由专科医生诊断为应激障碍的患者64例(男性32例、女性32例)通过信封法,分成安慰剂(P)组、乳酸菌组(L)组、和乳酸菌+葡甘露聚糖(M)组这3组,通过双盲法试验了本发明的制剂的效果。
各组的受检者的年龄和性别没有统计学的显著性差异。将构成各组的受检者的详细情况示于表1中。
表1:各组的受检者的详细情况
男性 | 女性 | 合计 | 年龄 | |
P组 | 11 | 12 | 23 | 34.5±9.6 |
L组 | 10 | 10 | 20 | 35.2±9.2 |
M组 | 11 | 10 | 21 | 35.6±13.1 |
合计 | 32 | 32 | 64 | 35.1±10.5 |
使P组、L组、或M组分别以1天3胶囊(1次1胶囊)的量在刚进餐后服用如上所述的比较例、制造例2、或制造例1的胶囊。施与期间为3个月。
<应激障碍的评价>
评价通过CHCW进行。在施与开始前和结束后,使各受检者填写CHCW,比较了变化。为了保护个人信息,问卷的个人名擦掉,以编号显示。
算出关于全部项目的分数的合计,进行了评价。CHCW的30项目以1~5评价,5为“最好”,1为“最差”。因此,150分为最高,其反映完全没有应激的状态,30分为最低,被评价为最应激的状态。应激障碍以82分以下作为标准而综合地诊断。
统计数字以平均值±标准偏差表现,通过MAC版、统计软件SSMC来分析。
将结果示于图1和2中。
图1为将施与开始前和结束后评分了的CHCW的变化进行了比较的图。施与前的各组间的值没有显著性差异。此外,关于P组,在施与后显著恶化了。另一方面,对于L组和M组,与施与前相比在施与后显著地改善了。如果将L组(**:p<0.01)与M组(***:p<0.001)进行比较,则M组改善的显著性差异大。
图2为将各组的CHCW的施与前后的变化率进行了比较的图。CHCW变化率如下算出:
变化率(%)=〔(施与后的CHCW-施与前的CHCW)/施与前的CHCW〕×100
如图2所示,相对于P组,对于L组(**:p<0.01)和M组(***:p<0.001),CHCW显著地上升了。如果将L组与M组比较,则对于M组,相对于L组,CHCW显著地上升了(※※:p<0.01)。
<安全性的研究>
关于各组,在施与开始前和施与结束后,采取血液和尿样本,进行全血细胞计数(红细胞、白细胞、血红蛋白、血细胞比容、血小板)、Alb、GOT、GPT、LDH、AlP、γ-GTP、淀粉酶、BUN、肌酸酐、血糖值、血红蛋白A1c、尿(蛋白、糖、***原)的检查,将结果进行了比较。
在施与前后,这些血液和尿检查的异常在哪个组中都未确认。作为副作用,软便在L组中观察到2例,在M组中观察到1例。
根据本研究的结果,对于施与了本发明的应激障碍的预防或改善用剂的组,在L组和M组中都改善了应激障碍。即,针对应激障碍,L组、M组与P组相比显著有效。如果将L组与M组进行比较,则M组更有效。L组、M组都作为副作用,仅在少数的受检者中观察到若干的轻微的软便,确认了本发明的制剂和组合物安全性非常高。
该申请基于2019年12月2日申请的日本专利申请、特愿2019-218218,特愿2019-218218的说明书和权利要求书所记载的内容全部被包含于该申请说明书。
Claims (11)
1.一种应激障碍的预防或改善用剂,以作为乳酸菌的德氏乳杆菌乳亚种(Lactobacillus delbrueckii subsp.lactis)或来源于该乳酸菌的成分作为有效成分。
2.根据权利要求1所述的应激障碍的预防或改善用剂,所述应激障碍为适应障碍、自主神经功能紊乱、抑郁反应、抑郁症、神经症性反应、躁郁症、焦虑症、惊恐障碍、睡眠障碍、癫痫、精神***症、非典型精神病中的任意1种以上。
3.根据权利要求1或2所述的应激障碍的预防或改善用剂,所述乳酸菌包含选自德氏乳杆菌乳亚种KLAB-4株(NITE BP-394)及其突变体中的乳酸菌。
4.根据权利要求1~3中任一项所述的应激障碍的预防或改善用剂,进一步含有水溶性食物纤维成分,或者
与水溶性食物纤维成分联合使用。
5.根据权利要求4所述的应激障碍的预防或改善用剂,所述水溶性食物纤维成分从葡甘露聚糖、果胶、瓜尔豆胶、海藻酸、聚右旋糖、β葡聚糖、果聚糖、菊糖、Levan型果聚糖、Graminan型果聚糖、***胶、麦芽糖醇、洋车前子、难消化性寡糖、难消化性糊精、琼脂糖、海藻酸钠、卡拉胶、岩藻多糖、紫菜聚糖(porphyran)、昆布多糖、海藻和琼脂中选择。
6.根据权利要求5所述的应激障碍的预防或改善用剂,所述水溶性食物纤维成分为葡甘露聚糖。
7.包含权利要求1~6中任一项所述的应激障碍的预防或改善用剂的组合物。
8.一种药物组合物,包含权利要求1~6中任一项所述的应激障碍的预防或改善用剂。
9.一种饮食品组合物,包含权利要求1~6中任一项所述的应激障碍的预防或改善用剂。
10.一种动物用饲料或动物用药物组合物,包含权利要求1~6中任一项所述的应激障碍的预防或改善用剂。
11.一种应激障碍的预防或改善方法,包括:向对象施与权利要求1~6中任一项所述的应激障碍的预防或改善用剂、或权利要求7~10中任一项所述的组合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019218218 | 2019-12-02 | ||
JP2019-218218 | 2019-12-02 | ||
PCT/JP2020/044055 WO2021111982A1 (ja) | 2019-12-02 | 2020-11-26 | ストレス障害の予防又は改善用剤及びそれを含む組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114746101A true CN114746101A (zh) | 2022-07-12 |
Family
ID=76221597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080083597.4A Pending CN114746101A (zh) | 2019-12-02 | 2020-11-26 | 应激障碍的预防或改善用剂和包含其的组合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230000933A1 (zh) |
EP (1) | EP4070807A1 (zh) |
JP (1) | JP7072965B2 (zh) |
CN (1) | CN114746101A (zh) |
WO (1) | WO2021111982A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102552609B1 (ko) * | 2022-07-07 | 2023-07-10 | 이우람 | 기억력, 학습력 향상 및 스트레스 완화용 총명환 조성물 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008081434A (ja) * | 2006-09-27 | 2008-04-10 | Univ Of Miyazaki | 気分改善剤 |
WO2008043161A1 (en) * | 2006-10-09 | 2008-04-17 | Maria Baltadjieva | Probiotic strain lactobacillus delbrueckii subsp . bulgaricus |
JP2011116666A (ja) * | 2009-11-30 | 2011-06-16 | Api Co Ltd | 乳酸菌発酵ローヤルゼリーを含有する抗ストレス剤及びその製造方法 |
WO2011111734A1 (ja) * | 2010-03-10 | 2011-09-15 | 株式会社カネカ | 乳酸菌含有製剤 |
CA2846213A1 (en) * | 2011-08-15 | 2013-02-21 | Nestec S.A. | Methods for ameliorating symptoms or conditions caused by stress |
CN105025909A (zh) * | 2013-02-27 | 2015-11-04 | 株式会社明治 | 应激减轻剂 |
CN109288874A (zh) * | 2018-11-22 | 2019-02-01 | 北京格特基因科技有限公司 | 能改善孤独症谱系障碍患者症状的益生菌 |
CN109789175A (zh) * | 2016-08-16 | 2019-05-21 | Md保健株式会社 | 预防或治疗精神障碍的含源自乳酸杆菌属细菌的囊泡的组合物 |
CN110366420A (zh) * | 2017-02-24 | 2019-10-22 | 森永乳业株式会社 | 心理健康障碍改善用组合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60173210A (ja) | 1984-02-17 | 1985-09-06 | Shigeto Kumagai | グラウンド等の排水装置 |
WO2009066681A1 (ja) * | 2007-11-19 | 2009-05-28 | Kaneka Corporation | 乳酸菌含有製剤 |
JP7079482B2 (ja) | 2018-06-15 | 2022-06-02 | 国立研究開発法人産業技術総合研究所 | カーボンナノチューブおよびカーボンナノチューブを含む廃液の処理方法 |
-
2020
- 2020-11-26 EP EP20897160.6A patent/EP4070807A1/en not_active Withdrawn
- 2020-11-26 CN CN202080083597.4A patent/CN114746101A/zh active Pending
- 2020-11-26 JP JP2021562611A patent/JP7072965B2/ja active Active
- 2020-11-26 WO PCT/JP2020/044055 patent/WO2021111982A1/ja unknown
- 2020-11-26 US US17/782,136 patent/US20230000933A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008081434A (ja) * | 2006-09-27 | 2008-04-10 | Univ Of Miyazaki | 気分改善剤 |
WO2008043161A1 (en) * | 2006-10-09 | 2008-04-17 | Maria Baltadjieva | Probiotic strain lactobacillus delbrueckii subsp . bulgaricus |
JP2011116666A (ja) * | 2009-11-30 | 2011-06-16 | Api Co Ltd | 乳酸菌発酵ローヤルゼリーを含有する抗ストレス剤及びその製造方法 |
WO2011111734A1 (ja) * | 2010-03-10 | 2011-09-15 | 株式会社カネカ | 乳酸菌含有製剤 |
CA2846213A1 (en) * | 2011-08-15 | 2013-02-21 | Nestec S.A. | Methods for ameliorating symptoms or conditions caused by stress |
CN105025909A (zh) * | 2013-02-27 | 2015-11-04 | 株式会社明治 | 应激减轻剂 |
CN109789175A (zh) * | 2016-08-16 | 2019-05-21 | Md保健株式会社 | 预防或治疗精神障碍的含源自乳酸杆菌属细菌的囊泡的组合物 |
CN110366420A (zh) * | 2017-02-24 | 2019-10-22 | 森永乳业株式会社 | 心理健康障碍改善用组合物 |
CN109288874A (zh) * | 2018-11-22 | 2019-02-01 | 北京格特基因科技有限公司 | 能改善孤独症谱系障碍患者症状的益生菌 |
Non-Patent Citations (3)
Title |
---|
MISRA S: "Psychobiotics: A new approach for treating mental illness?", CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, vol. 59, no. 8, pages 1 - 7 * |
李瑞盈等: "脑-肠轴与精神疾病肠道微生物的研究进展", 食品工业科技, vol. 42, no. 18, pages 427 - 434 * |
梁仙志等: "肠道微生物群与部分人类疾病的研究进展", 基因组学与应用生物学, vol. 39, no. 12, pages 5874 - 5880 * |
Also Published As
Publication number | Publication date |
---|---|
US20230000933A1 (en) | 2023-01-05 |
JP7072965B2 (ja) | 2022-05-23 |
JPWO2021111982A1 (zh) | 2021-06-10 |
EP4070807A1 (en) | 2022-10-12 |
WO2021111982A1 (ja) | 2021-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Waitzberg et al. | Effect of synbiotic in constipated adult women–a randomized, double-blind, placebo-controlled study of clinical response | |
EP3501527B1 (en) | Composition for preventing or treating mental disorder, containinglactobacillus | |
JP5868843B2 (ja) | 乳酸菌含有製剤 | |
JP5554994B2 (ja) | 乳酸菌含有製剤 | |
JP7280069B2 (ja) | 機能性消化管障害予防又は改善用組成物、並びに、該機能性消化管障害予防又は改善用組成物を用いた医薬品組成物及び飲食品組成物 | |
JP7323510B2 (ja) | 睡眠促進用組成物並びに該睡眠促進用組成物を用いた医薬品組成物及び飲食品組成物 | |
KR20200138333A (ko) | 염증성 장 질환을 치료하는 조성물 및 방법 | |
AU2018225957B2 (en) | Composition for alleviating mental health disorder | |
US20240180979A1 (en) | Composition for suppressing or improving eye fatigue | |
CN114746101A (zh) | 应激障碍的预防或改善用剂和包含其的组合物 | |
EP3928637A1 (en) | Kimchi lactobacillus sakei having prophylactic, ameliorating or therapeutic effect on depression and anxiety disorders | |
JP7057039B2 (ja) | 認知症の予防又は改善用剤及びそれを含む組成物 | |
EP3782632A1 (en) | Anti-stress composition | |
JP7072966B2 (ja) | 機能性身体症候群の予防又は改善用剤及びそれを含む組成物 | |
JP2021138776A (ja) | 下痢型過敏性腸症候群抑制剤及び食品組成物 | |
JP7063514B2 (ja) | 起立性低血圧の予防又は改善用剤及びそれを含む組成物 | |
JP7430172B2 (ja) | 腸内菌叢中のフィーカリバクテリウム属菌の占有率を増加させるための組成物 | |
JP7345771B2 (ja) | 糖尿病によって誘発される知覚過敏または知覚異常の予防又は治療用組成物 | |
WO2022045138A1 (ja) | 腸内菌叢中の特定の細菌属の占有率を変化させるための組成物 | |
WO2024009689A1 (ja) | 便通改善剤 | |
JP2022060541A (ja) | 下痢型過敏性腸症候群抑制剤及び食品組成物 | |
CN117813104A (zh) | 用于治疗或预防ibs相关焦虑的含巴氏灭菌阿克曼氏菌的组合物 | |
Drmosh et al. | Department of Therapeutic Nutrition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |